Beta-blockers in COPD: time for reappraisal

Brian Lipworth , Jadwiga Wedzicha, Graham Devereux, Jørgen Vestbo, Mark Dransfield

Research output: Contribution to journalArticle

31 Citations (Scopus)
5 Downloads (Pure)

Abstract

The combined effects on the heart of smoking and hypoxaemia may contribute to an increased cardiovascular burden in COPD. The use of beta-blockers in COPD has been proposed because of their known cardio-protective effects as well as reducing heart rate and improving systolic function. Despite the proven cardiac benefits of beta-blockers post myocardial infarction and in heart failure they remain under used due to concerns regarding potential bronchoconstriction even with cardio-selectivedrugs. Initiating treatment with beta-blockers requires dose titration and monitoring over a period of weeks, and beta-blockers may be less well tolerated in olderpatients with COPD who have other comorbidities. Medium term prospective placebo controlled safety studies in COPD are warranted to reassure prescribers regarding the pulmonary and cardiac tolerability of beta-blockers as well as evaluating their potential interaction with concomitant inhaled long acting bronchodilator therapy.Several retrospective observational studies have shown impressive reductions inmortality and exacerbations conferred by beta-blockers in COPD. However, this requires confirmation from long term prospective placebo controlled randomized controlled trials. The real challenge is to establish whether beta-blockers confer benefits on mortality and exacerbations in all patients with COPD including those with silent cardiovascular disease where the situation is less clear.
Original languageEnglish
Pages (from-to)880-888
Number of pages9
JournalEuropean Respiratory Journal
Volume48
Issue number3
Early online date31 Aug 2016
DOIs
Publication statusPublished - 1 Sep 2016

Fingerprint

Chronic Obstructive Pulmonary Disease
Placebos
Bronchoconstriction
Bronchodilator Agents
Observational Studies
Comorbidity
Cardiovascular Diseases
Randomized Controlled Trials
Heart Failure
Retrospective Studies
Heart Rate
Smoking
Myocardial Infarction
Safety
Lung
Mortality
Therapeutics

Keywords

  • COPD
  • beta-blocker
  • coronary artery disease
  • heart failure
  • exacerbations

Cite this

Lipworth , B., Wedzicha, J., Devereux, G., Vestbo, J., & Dransfield, M. (2016). Beta-blockers in COPD: time for reappraisal. European Respiratory Journal, 48(3), 880-888. https://doi.org/10.1183/13993003.01847-2015

Beta-blockers in COPD : time for reappraisal. / Lipworth , Brian; Wedzicha, Jadwiga; Devereux, Graham; Vestbo, Jørgen; Dransfield, Mark.

In: European Respiratory Journal, Vol. 48, No. 3, 01.09.2016, p. 880-888.

Research output: Contribution to journalArticle

Lipworth , B, Wedzicha, J, Devereux, G, Vestbo, J & Dransfield, M 2016, 'Beta-blockers in COPD: time for reappraisal', European Respiratory Journal, vol. 48, no. 3, pp. 880-888. https://doi.org/10.1183/13993003.01847-2015
Lipworth , Brian ; Wedzicha, Jadwiga ; Devereux, Graham ; Vestbo, Jørgen ; Dransfield, Mark. / Beta-blockers in COPD : time for reappraisal. In: European Respiratory Journal. 2016 ; Vol. 48, No. 3. pp. 880-888.
@article{64a5bc547491461799e95a797e6dd206,
title = "Beta-blockers in COPD: time for reappraisal",
abstract = "The combined effects on the heart of smoking and hypoxaemia may contribute to an increased cardiovascular burden in COPD. The use of beta-blockers in COPD has been proposed because of their known cardio-protective effects as well as reducing heart rate and improving systolic function. Despite the proven cardiac benefits of beta-blockers post myocardial infarction and in heart failure they remain under used due to concerns regarding potential bronchoconstriction even with cardio-selectivedrugs. Initiating treatment with beta-blockers requires dose titration and monitoring over a period of weeks, and beta-blockers may be less well tolerated in olderpatients with COPD who have other comorbidities. Medium term prospective placebo controlled safety studies in COPD are warranted to reassure prescribers regarding the pulmonary and cardiac tolerability of beta-blockers as well as evaluating their potential interaction with concomitant inhaled long acting bronchodilator therapy.Several retrospective observational studies have shown impressive reductions inmortality and exacerbations conferred by beta-blockers in COPD. However, this requires confirmation from long term prospective placebo controlled randomized controlled trials. The real challenge is to establish whether beta-blockers confer benefits on mortality and exacerbations in all patients with COPD including those with silent cardiovascular disease where the situation is less clear.",
keywords = "COPD, beta-blocker, coronary artery disease, heart failure, exacerbations",
author = "Brian Lipworth and Jadwiga Wedzicha and Graham Devereux and J{\o}rgen Vestbo and Mark Dransfield",
year = "2016",
month = "9",
day = "1",
doi = "10.1183/13993003.01847-2015",
language = "English",
volume = "48",
pages = "880--888",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",

}

TY - JOUR

T1 - Beta-blockers in COPD

T2 - time for reappraisal

AU - Lipworth , Brian

AU - Wedzicha, Jadwiga

AU - Devereux, Graham

AU - Vestbo, Jørgen

AU - Dransfield, Mark

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The combined effects on the heart of smoking and hypoxaemia may contribute to an increased cardiovascular burden in COPD. The use of beta-blockers in COPD has been proposed because of their known cardio-protective effects as well as reducing heart rate and improving systolic function. Despite the proven cardiac benefits of beta-blockers post myocardial infarction and in heart failure they remain under used due to concerns regarding potential bronchoconstriction even with cardio-selectivedrugs. Initiating treatment with beta-blockers requires dose titration and monitoring over a period of weeks, and beta-blockers may be less well tolerated in olderpatients with COPD who have other comorbidities. Medium term prospective placebo controlled safety studies in COPD are warranted to reassure prescribers regarding the pulmonary and cardiac tolerability of beta-blockers as well as evaluating their potential interaction with concomitant inhaled long acting bronchodilator therapy.Several retrospective observational studies have shown impressive reductions inmortality and exacerbations conferred by beta-blockers in COPD. However, this requires confirmation from long term prospective placebo controlled randomized controlled trials. The real challenge is to establish whether beta-blockers confer benefits on mortality and exacerbations in all patients with COPD including those with silent cardiovascular disease where the situation is less clear.

AB - The combined effects on the heart of smoking and hypoxaemia may contribute to an increased cardiovascular burden in COPD. The use of beta-blockers in COPD has been proposed because of their known cardio-protective effects as well as reducing heart rate and improving systolic function. Despite the proven cardiac benefits of beta-blockers post myocardial infarction and in heart failure they remain under used due to concerns regarding potential bronchoconstriction even with cardio-selectivedrugs. Initiating treatment with beta-blockers requires dose titration and monitoring over a period of weeks, and beta-blockers may be less well tolerated in olderpatients with COPD who have other comorbidities. Medium term prospective placebo controlled safety studies in COPD are warranted to reassure prescribers regarding the pulmonary and cardiac tolerability of beta-blockers as well as evaluating their potential interaction with concomitant inhaled long acting bronchodilator therapy.Several retrospective observational studies have shown impressive reductions inmortality and exacerbations conferred by beta-blockers in COPD. However, this requires confirmation from long term prospective placebo controlled randomized controlled trials. The real challenge is to establish whether beta-blockers confer benefits on mortality and exacerbations in all patients with COPD including those with silent cardiovascular disease where the situation is less clear.

KW - COPD

KW - beta-blocker

KW - coronary artery disease

KW - heart failure

KW - exacerbations

U2 - 10.1183/13993003.01847-2015

DO - 10.1183/13993003.01847-2015

M3 - Article

VL - 48

SP - 880

EP - 888

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 3

ER -